Although SOX2 itself, as a transcription factor, is not an optimal target for small-molecule therapy, this study posits the targeting of the associated E3 ligase as a promising strategy for treating cancers driven by aberrant SOX2 expression. The gene discussed is SOX2; the disease is cancer.